To include your compound in the COVID-19 Resource Center, submit it here.

Via Synpromics takeout, AskBio adds promoters to gene therapy platform

With the acquisition of Synpromics, well-funded gene therapy developer AskBio has added synthetic promoter technology to its toolkit as it prepares to begin clinical testing of four candidates by YE20.

The takeout comes about three months after 18-year-old Asklepios

Read the full 395 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers